Solid Biosciences Target of Unusually High Options Trading (NASDAQ:SLDB)
Solid Biosciences Inc (NASDAQ:SLDB) was the target of unusually large options trading on Monday. Investors purchased 615 call options on the stock. This is an increase of 892% compared to the typical volume of 62 call options.
In related news, Director Juan Andrey Zarur sold 8,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $10.00, for a total transaction of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 31.20% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of SLDB. Rhumbline Advisers grew its stake in shares of Solid Biosciences by 57.7% in the 4th quarter. Rhumbline Advisers now owns 15,644 shares of the company’s stock valued at $419,000 after buying an additional 5,725 shares during the period. New York State Common Retirement Fund grew its stake in shares of Solid Biosciences by 28.6% in the 4th quarter. New York State Common Retirement Fund now owns 13,500 shares of the company’s stock valued at $362,000 after buying an additional 3,000 shares during the period. BlackRock Inc. grew its stake in shares of Solid Biosciences by 56.0% in the 4th quarter. BlackRock Inc. now owns 1,214,410 shares of the company’s stock valued at $32,546,000 after buying an additional 436,161 shares during the period. Bank of New York Mellon Corp boosted its stake in Solid Biosciences by 35.7% during the 4th quarter. Bank of New York Mellon Corp now owns 56,703 shares of the company’s stock valued at $1,520,000 after purchasing an additional 14,925 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Solid Biosciences by 2.3% during the 4th quarter. Northern Trust Corp now owns 170,652 shares of the company’s stock valued at $4,573,000 after purchasing an additional 3,804 shares during the last quarter. Institutional investors own 59.41% of the company’s stock.
Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Monday, May 13th. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.22). Equities research analysts predict that Solid Biosciences will post -3.09 earnings per share for the current fiscal year.
A number of analysts have weighed in on the company. ValuEngine downgraded Woodward, Inc.Common Stock from a “buy” rating to a “hold” rating in a report on Tuesday, April 9th. Zacks Investment Research downgraded Zai Lab from a “buy” rating to a “hold” rating in a report on Saturday, June 15th. Goldman Sachs Group downgraded E.ON SE Sponsored ADR (Germany) from a “buy” rating to a “neutral” rating in a report on Tuesday, May 14th. Credit Suisse Group set a €19.00 ($22.09) price target on K&S and gave the stock a “neutral” rating in a report on Tuesday, May 14th. Finally, Citigroup set a $6.00 price target on Solid Biosciences and gave the stock a “hold” rating in a report on Thursday, May 16th. Three equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $6.35.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.